The Program in Cancer Biology is focused on investigations into mechanisms and signaling pathways involved in the malignant transformation of cells. The goals are to advance basic understanding of cancer pathogenesis and to translate basic science discoveries into the clinical arena to improve the outcome of patients with cancer. The Program encompasses three major thematic groups: 1) Mechanisms and Pathways of Oncogenesis;2) Cell Cycle, Cytoskeleton and Genomic Stability;and 3) Epithelial Neoplasia (including skin, prostate and lung cancer subgroups). Investigations are focused on mechanistic studies of oncogenes and tumor suppressor genes, the control of cell division, genomic stability and DNA damage checkpoints, as well as disease-specific interests in hematologic malignancies, skin, prostate and lung cancers. The 40 investigators represent two different schools (the School of Medicine and the School of Humanities &Sciences), 16 Departments, and five Divisions within the Department of Medicine. The research activities of the 40 investigators are supported by 73 peer-reviewed, investigator-initiated grants (R01s and others), and five T32 training awards. Total NCI support is $4.3 million, other NIH support is $7.2 million, and non-NIH support is $3.2 million. Since 2005, program investigators have published over 400 manuscripts relevant to cancer biology in peer-reviewed journals. The Cancer Center will continue to be invaluable in assisting with the translation of the basic science findings from this Program into new clinical approaches for the diagnosis and treatment of patients with cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442
Gee, Marvin H; Han, Arnold; Lofgren, Shane M et al. (2018) Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell 172:549-563.e16
Malta, Tathiane M; Sokolov, Artem; Gentles, Andrew J et al. (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173:338-354.e15
Banerjee, Imon; Gensheimer, Michael Francis; Wood, Douglas J et al. (2018) Probabilistic Prognostic Estimates of Survival in Metastatic Cancer Patients (PPES-Met) Utilizing Free-Text Clinical Narratives. Sci Rep 8:10037
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Rogers, Zoë N; McFarland, Christopher D; Winters, Ian P et al. (2018) Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. Nat Genet 50:483-486
Nair, Viswam S; Sundaram, Vandana; Desai, Manisha et al. (2018) Accuracy of Models to Identify Lung Nodule Cancer Risk in the National Lung Screening Trial. Am J Respir Crit Care Med 197:1220-1223
She, Richard; Jarosz, Daniel F (2018) Mapping Causal Variants with Single-Nucleotide Resolution Reveals Biochemical Drivers of Phenotypic Change. Cell 172:478-490.e15

Showing the most recent 10 out of 322 publications